Skip to main content

Table 9 Differences in the approach to a second line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment Compared groups n % (n) of physicians, who follow the guidelines % (n) of physicians, who don’t follow the guidelines X2 p
First-generation H1-antihistamines Administer 156 13.1 (136) 22.7 (20) 6.297 0.012
No 970 86.9 (902) 77.3 (68)
Second-generation H1-antihistamines at standard dose Administer 127 11.3 (117) 11.4 (10) 0.001 0.979
No 999 88.7 (921) 88.6 (78)
Updosed second-generation H1-antihistamines Administer 651 58.8 (610) 46.6 (41) 4.931 0.026
No 475 41.2 (428) 53.4 (47)
H2-antihistamines (e.g. famotidine or ranitidine) Administer 308 27.1 (281) 30.7 (27) 0.532 0.466
No 818 72.9 (757) 69.3 (61)
Ciclosporin Administer 76 6.8 (71) 5.7 (5) 0.173 0.678
No 1050 93.2 (967) 94.3 (83)
Omalizumab Administer 163 14.5 (150) 14.8 (13) 0.007 0.934
No 963 85.5 (888) 85.2 (75)
Montelukast Administer 391 35.5 (368) 26.1 (23) 3.106 0.078
No 735 64.5 (670) 73.9 (65)
Dapsone Administer 39 3.2 (33) 6.8 (6) 3.213 0.073
No 1087 96.8 (1005) 93.2 (82)
Systemic corticosteroids (for less than 10 days) Administer 265 23.8 (247) 20.5 (18) 0.503 0.478
No 861 76.2 (791) 79.5 (70)
Systemic corticosteroids (for more than 10 days in a row) Administer 89 7.4 (77) 13.6 (12) 4.309 0.038
No 1037 92.6 (961) 86.4 (76)
Tricyclic antidepressants (e.g. doxepin) Administer 137 11.6 (120) 19.3 (17) 4.568 0.033
No 989 88.4 (918) 80.7 (71)
  1. Values marked in bold indicate a statistically significant difference (p < 0.05)